Stock Analiz

GeoVax Labs, Inc. GOVX

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$1.71Market cap $928292
Open the interactive analysis →

GeoVax Labs, Inc. (GOVX) is a healthcare company listed in the US with a market value of about $928292. In fiscal year 2025 it had revenue of $2M and net income of -$21M, a net margin of -862.3%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is value (2/5); the weakest is track record (0/5).

Key numbers: a P/E of 0.0, 5-year revenue growth of 6% a year, a 5-year average ROIC of -301%.

About GeoVax Labs

GeoVax Labs is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $828918 in 2016 to $2M in 2025, growth of about 13.0% a year. It was profitable in 0 of the last 10 years in our data. Its share count fell by 15% over three years (buybacks). It spends 728% of revenue on research and development.

Score: 1.2 / 5

Value2/5
Future growth1/5
Track record0/5
Financial health2/5
Shareholder returns1/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • 3-year revenue growth above 10% a year
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets
  • Share count down over 3 years (buybacks)

Checks not passed

  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year
  • Strong R&D investment or growth above 20%
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)0.0
Forward P/E—
P/FCF—
P/S—
P/B0.8
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-1777.3%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-37.1%
Revenue growth (5 yrs, per year)6.4%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-5877.5%
ROIC (5-yr avg.)-301.5%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue$2M$4M$0$81526$385501$2M$1M$963203$1M$828918
Net income-$21M-$25M-$26M-$14M-$19M-$3M-$2M-$3M-$2M-$3M
Free cash flow-$22M-$25M-$25M-$19M-$11M-$3M-$1M—-$2M—
EPS (diluted)$-22.40$-120.46$-14.29$-12.39$-3.04$-2.14$-781.87$-310981.25$-596131.89$-1589685.05
Net margin-862.3%-632.0%—-17198.3%-4817.2%-162.2%-201.6%-265.8%-201.8%-394.7%
ROIC-366.2%-393.5%-366.6%-41.7%-339.5%-22.8%———-1075.8%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 2 analysts is $240.00, 13976% above the current price; targets range from $240.00 to $240.00; the consensus rating is “none”; expected EPS is $-123.36 for the fiscal year ending December 31, 2026.

Frequently asked questions

What is GeoVax Labs’s P/E ratio?

About 0.0, based on the last twelve months of diluted earnings per share.

Does GeoVax Labs pay a dividend?

Not currently.

Is GeoVax Labs a good stock to buy?

We do not give buy or sell advice. GeoVax Labs scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.